Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FOP
|
|||
| Drug Name |
Ravulizumab
|
|||
| Synonyms |
Ultomiris (TN); Ravulizumab (USAN); Ravulizumab (genetical recombination) (JAN); D11054; 1803171-55-2
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 3 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN complement C5 protein (C5) | Target Info | Inhibitor | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 761108. | |||
| REF 2 | ClinicalTrials.gov (NCT04369469) Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia. U.S. National Institutes of Health. | |||
| REF 3 | Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23. | |||
| REF 4 | ULTOMIRIS (ravulizumab cwvz) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.